News
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
Media
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
Publications
All Journals
For Authors
Tumor Board
Events
Frontline Forum
CME/CE
Resources
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Subscribe
Print Subscription
eNewsletter

logo
Spotlight
Around the Practice
Between the Lines
Contemporary Concepts
Journal
OncView
Podcasts
Readout 360
2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
CancerNetwork® Inaugural Face-Off
Contemporary Concepts in Hematologic Oncology
Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer
Clinical
Acute Myeloid Leukemia
Brain Cancer
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Gynecologic Cancer
Hematology
Leukemia
Lung Cancer
Lymphoma
Pediatric Cancers
Skin Cancer
Clinical Topics
Integrative Care
Global Bulletin
All News
Approval Alert
2 Minute Drill
Around the Practice
Between the Lines
Clinical Consult
Expert Interviews
Face Off
Medical World News
Morning Rounds
OncView
Podcasts
Readout 360
Satellite Sessions
Sponsored Media
Training Academy
Year in Review
Conferences
All Journals
For Authors
Tumor Board
Frontline Forum
CME/CE
Contemporary Concepts
Awareness Month
Interactive Tools
Nurse Practitioners/Physician's Assistants
Partners
Sponsored
Print Subscription
eNewsletter
Advertisement
Breast Cancer
| Kidney Cancer
| Leukemia
| Lymphoma
| Multiple Myeloma
| Non-Small Cell Lung Cancer (NSCLC)
| Small Cell Lung Cancer (SCLC)
| Adverse Effects
| Biomarkers
| Bladder Cancer
| Brain Cancer
| Cervical Cancer
| Colorectal Cancer
| Endometrial Cancer
| Esophageal Cancer
| Gastrointestinal Cancer
| Genitourinary Cancers
| Gynecologic Cancers
| Head & Neck Cancer
| Hematology
| Hormone-related Cancers
| Immunotherapy
| Infection
| Liver Cancer
| Lung Cancer
| Mesothelioma
| Neuroendocrine Tumors
| Oncology
| Ovarian Cancer
| Ovarian Cancer Clincal Consult
| Pancreatic Cancer
| Pediatric Cancers
| Prostate Cancer
| Radiation Oncology
| Sarcoma
| Screening
| Skin Cancer & Melanoma
| Surgery
| Thoracic Malignancies
| Thyroid Cancer
View All >>
  • Adverse Effects
  • Biomarkers
  • Bladder Cancer
  • Brain Cancer
  • Breast Cancer
  • Cervical Cancer
  • Colorectal Cancer
  • Endometrial Cancer
  • Esophageal Cancer
  • Gastrointestinal Cancer
  • Genitourinary Cancers
  • Gynecologic Cancers
  • Head & Neck Cancer
  • Hematology
  • Hormone-related Cancers
  • Immunotherapy
  • Infection
  • Kidney Cancer
  • Leukemia
  • Liver Cancer
  • Lung Cancer
  • Lymphoma
  • Mesothelioma
  • Multiple Myeloma
  • Neuroendocrine Tumors
  • Non-Small Cell Lung Cancer (NSCLC)
  • Oncology
  • Ovarian Cancer
  • Ovarian Cancer Clincal Consult
  • Pancreatic Cancer
  • Pediatric Cancers
  • Prostate Cancer
  • Radiation Oncology
  • Sarcoma
  • Screening
  • Skin Cancer & Melanoma
  • Small Cell Lung Cancer (SCLC)
  • Surgery
  • Thoracic Malignancies
  • Thyroid Cancer

SPOTLIGHT -

Around the Practice
| Between the Lines
| Contemporary Concepts
| Journal
| OncView
| Podcasts
| Readout 360
| 2022 ASCO Genitourinary Cancers Symposium Urothelial Cancer Updates
| CancerNetwork® Inaugural Face-Off
| Contemporary Concepts in Hematologic Oncology
| Insights from Experts at Mayo Clinic on Translating Evidence to Clinical Practice
| Optimizing Outcomes in Patients with HER2+ Metastatic Breast Cancer

AUA: Studies Highlight Links Between Bladder Cancer, E-Cigarettes

May 15, 2017
Dave Levitan
Article

New studies at the AUA Annual Meeting highlight the links between smoking and bladder cancer. In one, smoking intensity was linked to survival outcomes, while two others show that electronic cigarettes likely contribute to bladder cancer risk.

Several new studies presented at the Annual Scientific meeting of the American Urological Association (AUA) highlight the important links between smoking and bladder cancer. In one, smoking intensity was linked to survival outcomes in bladder cancer patients, while two others show that electronic cigarettes likely contribute to bladder cancer risk.

“This research underscores the importance of smoking cessation (of both traditional and e-cigarettes) for people with bladder cancer, and people looking to avoid it,” said Sam S. Chang, MD, MBA, of Vanderbilt–Ingram Cancer Center in Nashville, who moderated the session with the new studies, in a press release.

The first study, led by Luis Felipe Sávio, MD, of the University of Miami Miller School of Medicine in Florida, used the Florida Cancer Data System to identify 14,077 bladder cancer patients who smoked. Of those, 25% smoked less than one pack of cigarettes per day, 63% smoked between one and two packs per day, and 12% smoked more than two packs per day.

The median overall survival (OS) for the full cohort was 4 years, and the 5-year OS rate was 43.7%. For those who smoked less than one, one to two, and more than two packs per day, the median OS was 4.2 years, 3.9 years, and 4.1 years, respectively; 5-year OS rates for these groups were 45.1%, 43.1%, and 43.6%, respectively. Using the group that smoked less than one pack as a reference, those smoking one to two packs daily had a hazard ratio (HR) for mortality of 1.11 (95% CI, 1.06–1.16; P < .001); for more than two packs per day, the HR was 1.08 (95% CI, 1.00–1.16; P = .042).

The other studies focused on e-cigarettes. Thomas Fuller, MD, of the University of Pittsburgh, led a study that compared the urine of 13 e-cigarette users to 10 non-smokers, analyzing them for five known bladder carcinogens: benz(a)anthracene, benzo(a)pyrene, 1-hydroxypyrene, o-toluidine, and 2-naphthylamine.

Two of those five molecules-o-toluidine and 2-naphthylamine-were found in urine of 12 of the 13 e-cigarette users. They were found in none of the control participants, and the other three carcinogens were not found in any of the participants.

In the other study, led by Hyun-Wook Lee, PhD, of New York University School of Medicine, researchers using a mouse model found that e-cigarette smoke can induce tumorigenic DNA damage in bladder mucosa. This was also seen in an in vitro experiment using human urothelial cells.

“These studies raise new concerns about the harmful impact of e-cigarettes on bladder cancer,” Chang said. “We’ve known traditional smoking raises bladder cancer risk, and given the surge in popularity of e-cigarettes, it’s imperative we uncover any potential links to e-cigarette smoke and bladder cancer.”

Related Videos
Experts on bladder cancer
Experts on bladder cancer
Experts on bladder cancer
Experts on bladder cancer
Experts on bladder cancer
Experts on bladder cancer
Experts on bladder cancer
Experts on bladder cancer
Experts on bladder cancer
Experts on bladder cancer
Related Content

EMA Accepts Application for Erdafitinib in EGFR+ Urothelial Carcinoma

September 11th 2023

Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

March 15th 2022

FDA Accepts sNDA for Erdafitinib in FGFR+ Advanced Urothelial Carcinoma

August 29th 2023

Emerging Immunotherapy Approaches For Urothelial Cancer

February 4th 2019

Legislation Needed to Overcome Chemo Shortage; Expert Discusses Impact in GU

August 10th 2023

UGN-102 May be an Effective Non-Surgical Option For Bladder Cancer Subtype

August 4th 2023

EMA Accepts Application for Erdafitinib in EGFR+ Urothelial Carcinoma

September 11th 2023

Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

March 15th 2022

FDA Accepts sNDA for Erdafitinib in FGFR+ Advanced Urothelial Carcinoma

August 29th 2023

Emerging Immunotherapy Approaches For Urothelial Cancer

February 4th 2019

Legislation Needed to Overcome Chemo Shortage; Expert Discusses Impact in GU

August 10th 2023

UGN-102 May be an Effective Non-Surgical Option For Bladder Cancer Subtype

August 4th 2023

EMA Accepts Application for Erdafitinib in EGFR+ Urothelial Carcinoma

September 11th 2023

Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

March 15th 2022

FDA Accepts sNDA for Erdafitinib in FGFR+ Advanced Urothelial Carcinoma

August 29th 2023

Emerging Immunotherapy Approaches For Urothelial Cancer

February 4th 2019

Legislation Needed to Overcome Chemo Shortage; Expert Discusses Impact in GU

August 10th 2023

UGN-102 May be an Effective Non-Surgical Option For Bladder Cancer Subtype

August 4th 2023
Related Content
Advertisement

EMA Accepts Application for Erdafitinib in EGFR+ Urothelial Carcinoma | Image Credit: © SciePro - stock.adobe.com.

EMA Accepts Application for Erdafitinib in EGFR+ Urothelial Carcinoma

September 11th 2023
Article

Findings from the phase 3 THOR study support the marketing authorization application for erdafitinib as a treatment for those with advanced or metastatic urothelial cancer harboring FGFR3 alterations.


Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Oncology Peer Review On-The-Go: Neoadjuvant Chemotherapy for Elderly Patients with Muscle-Invasive Bladder Cancer

March 15th 2022
Podcast

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.


Data from the phase 3 THOR study support the supplemental biologics license application for erdafitinib in previously treated advanced or metastatic urothelial carcinoma with FGFR3 alterations.

FDA Accepts sNDA for Erdafitinib in FGFR+ Advanced Urothelial Carcinoma

August 29th 2023
Article

Data from the phase 3 THOR study support the supplemental biologics license application for erdafitinib in previously treated advanced or metastatic urothelial carcinoma with FGFR3 alterations.


Emerging Immunotherapy Approaches For Urothelial Cancer

Emerging Immunotherapy Approaches For Urothelial Cancer

February 4th 2019
Podcast

Cancer Network spoke with Dr. Petros Grivas about emerging immunotherapy approaches for the treatment of advanced urothelial cancer.


Amid the recent cisplatin shortages across the United States, a pharmacy expert discusses how the treatment of bladder cancer has been affected, especially in the muscle-invasive subtype.

Legislation Needed to Overcome Chemo Shortage; Expert Discusses Impact in GU

August 10th 2023
Article

Amid the recent cisplatin shortages across the United States, a pharmacy expert discusses how the treatment of bladder cancer has been affected, especially in the muscle-invasive subtype.


Among patients with low-grade, non–muscle invasive bladder cancer, intravesical UGN-102 appears to improve outcomes vs standard surgical treatment in two phase 3 trials.

UGN-102 May be an Effective Non-Surgical Option For Bladder Cancer Subtype

August 4th 2023
Article

Among patients with low-grade, non–muscle invasive bladder cancer, intravesical UGN-102 appears to improve outcomes vs standard surgical treatment in two phase 3 trials.

About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.